San Diego, CALIFORNIA3 Active Studies

Neuroendocrine Tumors Clinical Trials in San Diego, CALIFORNIA

Find 3 actively recruiting neuroendocrine tumors clinical trials in San Diego, CALIFORNIA. Connect with local research sites and explore new treatment options.

3
Active Trials
2
Sponsors
79
Enrolling

Recruiting Neuroendocrine Tumors Studies in San Diego

About Neuroendocrine Tumors Clinical Trials in San Diego

Neuroendocrine tumors (NETs) develop from hormone-producing cells and can occur in many organs, most commonly the gastrointestinal tract and lungs. They range from slow-growing to aggressive. Treatment includes surgery, somatostatin analogs, targeted therapy, and peptide receptor radionuclide therapy.

There are currently 3 neuroendocrine tumors clinical trials recruiting participants in San Diego, CALIFORNIA. These studies are seeking a combined 79 participants. Research is being sponsored by Quoin Pharmaceuticals, Jonsson Comprehensive Cancer Center. Clinical trial participation is free and participants receive study-related medical care at no cost.

Neuroendocrine Tumors Clinical Trials in San Diego — FAQ

Are there neuroendocrine tumors clinical trials in San Diego?

Yes, there are 3 neuroendocrine tumors clinical trials currently recruiting in San Diego, CALIFORNIA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in San Diego?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the San Diego research site will contact you about next steps.

Are clinical trials in San Diego free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many San Diego studies also compensate for your time and travel.

What neuroendocrine tumors treatments are being tested?

The 3 active trials in San Diego are testing new therapies including novel drugs, biologics, and treatment approaches for neuroendocrine tumors.

Data updated March 2, 2026 from ClinicalTrials.gov